These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1602 related articles for article (PubMed ID: 28758319)

  • 21. (90)Y-glass microspheres for hepatic neoplasia.
    Mahnken AH
    Future Oncol; 2015; 11(9):1343-54. PubMed ID: 25952780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
    Palmer DH; Hawkins NS; Vilgrain V; Pereira H; Chatellier G; Ross PJ
    Future Oncol; 2020 Jan; 16(1):4315-4325. PubMed ID: 31797680
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of the Adverse Event Profile of TheraSphere
    Kallini JR; Gabr A; Thorlund K; Balijepalli C; Ayres D; Kanters S; Ebrahim S; Mills E; Lewandowski RJ; Salem R
    Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1033-1043. PubMed ID: 28246879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
    Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
    BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of
    Mahvash A; Chartier S; Turco M; Habib P; Griffith S; Brown S; Kappadath SC
    BMC Gastroenterol; 2022 Mar; 22(1):151. PubMed ID: 35346070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Salem R; Lewandowski RJ
    Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
    Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
    JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
    Muszbek N; Remak E; Evans R; Brennan VK; Colaone F; Shergill S; Mullan D; Ross PJ
    Future Oncol; 2021 Mar; 17(9):1055-1068. PubMed ID: 33222542
    [No Abstract]   [Full Text] [Related]  

  • 30. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
    Chow PK; Gandhi M; Gebski V
    Future Oncol; 2017 Oct; 13(25):2213-2216. PubMed ID: 28976206
    [No Abstract]   [Full Text] [Related]  

  • 32. State of the art: radiolabeled microspheres treatment for liver malignancies.
    Deleporte A; Flamen P; Hendlisz A
    Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
    Minocha J; Salem R; Lewandowski RJ
    Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yttrium-90 (Y-90) Resin Microsphere Therapy for Patients with Unresectable Hepatocellular Carcinoma: a Single-Center Experience.
    İnce S; Karaman B; Alagoz E; Karadurmuş N; Şan H; Erçin CN; Arslan N
    J Gastrointest Cancer; 2017 Sep; 48(3):281. PubMed ID: 28634669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
    Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia.
    Liu DM; Leung TW; Chow PK; Ng DC; Lee RC; Kim YH; Mao Y; Cheng YF; Teng GJ; Lau WY
    Int J Surg; 2022 Jun; 102():106094. PubMed ID: 35662438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
    Kim DY; Han KH
    Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
    Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
    Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
    Tai D; Loke K; Gogna A; Kaya NA; Tan SH; Hennedige T; Ng D; Irani F; Lee J; Lim JQ; Too CW; Ng MCH; Tham CK; Lam J; Koo SL; Chong HS; Goh GB; Huang HL; Venkatanarasimha N; Lo R; Chow PKH; Goh BKP; Chung A; Toh HC; Thng CH; Lim TKH; Yeong J; Zhai W; Chan CY; Choo SP
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1025-1035. PubMed ID: 34695377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis.
    Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B
    J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 81.